Andrew Marks
11Patents
5h-index
5Co-inventors
55Inventor score
Filing activity: May 10, 2000 → Nov 7, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6489125B1 | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor | Physics | 9 | Expired |
| US7393652B2 | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) | Physics | 7 | Expired |
| US7312044B2 | Type 1 ryanodine receptor-based methods | Physics | 6 | Expired |
| US8022058B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | Chemistry; Metallurgy | 6 | Active |
| US8710045B2 | Agents for preventing and treating disorders involving modulation of the ryanodine receptors | Chemistry; Metallurgy | 5 | Active |
| US7662178B2 | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis | Human Necessities | 4 | Active |
| US7544678B2 | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | Physics | 2 | Active |
| US7879840B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | Chemistry; Metallurgy | 1 | Active |
| US7364586B2 | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis | Human Necessities | 1 | Expired |
| US7718644B2 | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | Human Necessities | 0 | Active |
| US10925976B2 | Smooth muscle specific inhibition for anti-restenotic therapy | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.